Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Forsteo ® (teriparatide)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Forsteo® (teriparatide): Use With COVID-19 Vaccines
The use of vaccines against SARS-CoV-2 in patients treated with teriparatide [rDNA origin] injection has not been studied.
Administration of COVID-19 Vaccines to Patients Receiving Teriparatide
Severe acute respiratory syndrome coronavirus 2 is an emerging virus that has caused the recent COVID-19 pandemic.1 Recently, vaccines have been developed against SARS-CoV-2 and additional vaccines are expected to be available in the coming months.2
SARS-CoV-2 Vaccination With Teriparatide
The use of a SARS-CoV-2 vaccine in patients treated with teriparatide has not been studied by Lilly.
Decisions regarding the use of any vaccination, including SARS-CoV-2 vaccines, in patients treated with teriparatide should be made at the discretion of the prescribing physician using their best clinical judgment, and must be made by the clinician after careful consideration of risk factors of the patient as well as the risks and benefits of vaccination. Consultation with an infectious disease expert may be helpful in high-risk or emergency situations such as the current COVID-19 pandemic.
Vaccination Against COVID-19 Treatment Guidance in Patients With Osteoporosis
Recommendations for the management of patients with osteoporosis in relation to COVID-19 vaccination have been published by the International Osteoporosis Foundation.3
For the most current information please refer to Joint Guidance on COVID-19 Vaccination and Osteoporosis Management.3
1Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):237. https://doi.org/10.1038/s41392-020-00352-y
2Su Z, Wen J, McDonnell D, et al. Vaccines are not yet a silver bullet: the imperative of continued communication about the importance of COVID-19 safety measures. Brain Behav Immun Health. 2021;12:100204. https://doi.org/10.1016/j.bbih.2021.100204
3Joint Guidance on COVID-19 Vaccination and Osteoporosis Management. The International Osteoporosis Foundation. March 9, 2021. Accessed March 26, 2021. https://www.osteoporosis.foundation/news/joint-guidance-covid-19-vaccination-and-osteoporosis-management-20210309-1500
4Coronavirus and osteoporosis. Royal Osteoporosis Society. December 11, 2020. Accessed May 3, 2021. https://theros.org.uk/information-and-support/osteoporosis/coronavirus/
5Coronavirus disease (COVID-19) outbreak. European web page of the World Health Organization. Accessed March 26, 2021. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19
6COVID-19. European Centre for Disease Prevention and Control. Accessed March 26, 2021. https://www.ecdc.europa.eu/en/novel-coronavirus-china
COVID-19 = coronavirus disease 2019
Lilly = Eli Lilly and Company
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
EU WHO = World Health Organization (European regional office)
ECDC = European Centre for Disease Prevention and Control
Date of Last Review: 11 January 2021